SNY
Sanofi trades as SNY and has a market capitalization of $53.13 B, making it the #308 largest US-listed company by market value. This page tracks Sanofi through 981 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Institutional holdings | 13F-HR | 2026-05-07 |
| SCHEDULE 13G | - | 2026-05-06 |
| 6-K | - | 2026-05-05 |
| 6-K | - | 2026-04-29 |
| 6-K | - | 2026-04-27 |
| 6-K | - | 2026-04-23 |
| 6-K | - | 2026-04-15 |
| SCHEDULE 13G/A | - | 2026-04-10 |
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Sanofi successfully prices 2.3 billion of bond issue
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Q1 2026: double-digit sales and business EPS growth
The largest companies sharing Sanofi's SEC industry classification (pharmaceutical preparations).
Sanofi (SNY) has a market capitalization of $53.13 B as of 2026-06-10, ranking #308 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.